Comprehensive Cancer Centers (Comprehensive) has announced the appointment of Samantha Barnes as director of public relations and government affairs. In this role, she leads strategic communications and public relations initiatives to position the practice as a world-class provider of oncology and pulmonary services.
Samantha brings a deep background in healthcare policy and legislative advocacy to the practice. Prior to joining Comprehensive, she spent seven years at Carrara Nevada, where she was instrumental in the successful passage of legislation to license genetic counselors in Nevada during the 2025 Legislative Session: a key initiative that expanded patient access to specialized care throughout the state.
“Samantha’s breadth of experience in stakeholder relations and her proven track record in community engagement makes her an invaluable addition to our leadership team,” said Lisa Santwer, Executive Director at Comprehensive. “Her expertise will be instrumental as we continue to enhance our patient-first mission and strengthen our presence within the community and at the legislative level.”
Samantha earned her Bachelor of Science in business management from the University of Nevada, Las Vegas. She leverages her background in strategic communication and advocacy to drive innovation and support Comprehensive’s commitment to providing high-quality care to patients across Southern Nevada.
About Comprehensive Cancer Centers
Comprehensive Cancer Centers is an award-winning multi-specialty practice comprising medical oncology, hematology, radiation oncology, breast surgery, pulmonary services, cancer genetic counseling clinical research and other infusion services, with treatment centers and offices throughout Southern Nevada. For more than 50 years, the practice has provided oncology services to patients in and out of state with a specialized physician and nursing staff. Comprehensive, an affiliate of The US Oncology Network, offers state-of-the-art technologies, latest advancements in cancer treatment and groundbreaking clinical research trials. The practice participates in more than 150 Phase I, Phase II and Phase III clinical research studies each year and has played a role in developing more than 100 FDA-approved cancer therapies. For more information, visit the company’s website.
